Home » Stocks » AMGN

Amgen Inc. (AMGN)

Stock Price: $254.21 USD 2.91 (1.16%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $254.51 +0.30 (0.12%) May 7, 7:42 PM
Market Cap 145.56B
Revenue (ttm) 25.16B
Net Income (ttm) 7.09B
Shares Out 577.00M
EPS (ttm) 12.07
PE Ratio 21.06
Forward PE 15.24
Dividend $6.56
Dividend Yield 2.58%
Trading Day May 7
Last Price $254.21
Previous Close $251.30
Change ($) 2.91
Change (%) 1.16%
Day's Open 251.78
Day's Range 251.65 - 255.73
Day's Volume 2,513,035
52-Week Range 207.32 - 274.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

THOUSAND OAKS, Calif., May 6, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Bank of America Merrill Lynch Virtual Healthcare Conference at 11:00 a.m.

1 day ago - PRNewsWire

THOUSAND OAKS, Calif., May 5, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sND...

2 days ago - PRNewsWire

There are certainly some problem spots for the big biotech.

2 days ago - The Motley Fool

The near future looks concerning for these companies in three different sectors. But for long-term investors, that can create opportunities.

Other stocks mentioned: BA, INTC
3 days ago - The Motley Fool

Amgen's Q1 results didn't bode well with the investors and the stock plunged over 7% in Wednesday's trading session (April 28). But now that the stock has fallen 9% in just five days, will AMGN stock re...

1 week ago - Forbes

Despite disappointing results that missed expectations, progress with an important new cancer drug saved the day.

1 week ago - The Motley Fool

High-quality pharmaceutical stocks comes with steady business, low valuations and solid dividend. Let's look at a handful of them now.

Other stocks mentioned: ABBV, BMY, JNJ, MRNA, PFE, SFY
1 week ago - InvestorPlace

Nobody seemed impressed by the company's latest quarterly results.

1 week ago - The Motley Fool

Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.

1 week ago - Zacks Investment Research

Amgen Inc (NASDAQ: AMGN) has a rough start this year after its Q1 March-quarter revenue slipped 4% from the year-ago quarter, while its earnings fell about 10%. Earnings: Even though unit volumes grew 4...

1 week ago - Benzinga

Precedent shows the best may be yet to come.

Other stocks mentioned: BNTX, NFLX, NVDA, PFE, TSLA
1 week ago - The Motley Fool

COVID-19 continued to negatively impact the big biotech.

1 week ago - The Motley Fool

THOUSAND OAKS, Calif., April 28, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it agreed last night with the FDA's proposed post-marketing requirement to conduct, as part of the ongoing ...

1 week ago - PRNewsWire

Amgen (AMGN) delivered earnings and revenue surprises of -7.50% and -5.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Other stocks mentioned: ABBV, AZN, BMY, GILD, JNJ, MRK
1 week ago - GuruFocus

U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healt...

1 week ago - Reuters

THOUSAND OAKS, Calif., April 27, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2021.

1 week ago - PRNewsWire

Amgen just bought Rodeo Therapeutics in a move that bolsters its drug candidate pipeline.

1 week ago - The Motley Fool

THOUSAND OAKS, Calif., April 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) improved measures of disease severity in adults with mild-to-moderate plaque psoriasis rega...

2 weeks ago - PRNewsWire

Bristol-Myers Squibb Co (NYSE: BMY) has announced new data from its two Phase 3 trials POETYK PSO-1 and POETYK PSO-2 for deucravacitinib, its oral, selective TYK2 inhibitor for moderate to severe plaque...

Other stocks mentioned: BMY
2 weeks ago - Benzinga

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

2 weeks ago - Zacks Investment Research

THOUSAND OAKS, Calif., April 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 27, 2021, after the close of the U.S. ...

2 weeks ago - PRNewsWire

Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.

Other stocks mentioned: BMY, REGN, REPL, RHHBY, SNY
2 weeks ago - GuruFocus

PRESS RELEASE:   REGULATED INFORMATION 22 April 2021, 07:01 CEST

2 weeks ago - GlobeNewsWire

Strategas' Chris Verrone lays out his hide-out trades

YouTube video

Strategas' Chris Verrone says brace yourself for market weakness. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Karen Finerman, Dan Nathan and Pete Najarian.

Other stocks mentioned: NEM, XLV
2 weeks ago - CNBC Television

Only a third of the stocks in the Dow rank as industry leaders according to MSCI's ESG rankings. Fortunately, most of those who do also are favored by Wall Street analysts.

Other stocks mentioned: AXP, CRM, CSCO, HD, HON, IBM, KO ...
2 weeks ago - Kiplinger

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

The FDA has granted Breakthrough Therapy Designation to Amgen Inc's (NASDAQ: AMGN) bemarituzumab for patients with gastric and gastroesophageal (GEJ) adenocarcinoma. The designation covers bemarituzumab...

2 weeks ago - Benzinga

THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational be...

2 weeks ago - PRNewsWire

THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of Biomarker Assist™ , a program to help more patients with metastatic (stage IV) non-small cell lun...

2 weeks ago - PRNewsWire

THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of c...

Other stocks mentioned: FPRX
3 weeks ago - PRNewsWire

Investment company Resource Planning Group (Current Portfolio) buys Amgen Inc, BTC iShares MSCI Emerging Markets Min Vol Factor E, Vanguard Small Cap Value ETF, Vanguard Value ETF, Schwab Fundamental In...

3 weeks ago - GuruFocus

2020 shows that investors need to be prepared for anything. These eight retirement stocks can do precisely that.

Other stocks mentioned: AMZN, COO, DG, MKC, NEE, VZ, ZTS ...
1 month ago - InvestorPlace

Amgen (AMGN) inks an agreement to acquire privately held company, Rodeo Therapeutics Corporation, to boost its inflammation portfolio.

1 month ago - Zacks Investment Research

The news: Pharmaceutical giant Amgen agreed to acquire Rodeo Therapeutics, a Seattle biotech startup creating small-molecule therapies that help repair and regrow tissues.

1 month ago - GeekWire

Although these stocks have been underperforming the S&P 500 over the past year, investors shouldn't ignore them.

Other stocks mentioned: ORCL, TRP
1 month ago - The Motley Fool

With blockbuster immunology treatments Enbrel (via $16 billion acquisition of Immunex in 2009) and Otezla (added in 2013 via $13 billion deal) already in its bag, Amgen Inc (NASDAQ: AMGN) has now put it...

Other stocks mentioned: TXAC
1 month ago - Benzinga

THOUSAND OAKS, Calif. and SEATTLE, March 30, 2021 /PRNewswire/ -- Amgen Inc. (NASDAQ:AMGN) and Rodeo Therapeutics Corporation (Rodeo) today announced an agreement under which Amgen will acquire Rodeo, a...

1 month ago - PRNewsWire

If you want to increase the resilience of your portfolio to make it stronger, the following three defensive stocks may suit you when economic conditions deteriorate.

Other stocks mentioned: PM, TGT
1 month ago - GuruFocus

The combination of growing earnings and generous payouts makes these companies attractive.

Other stocks mentioned: GRMN, HSY
1 month ago - The Motley Fool

Though most people reinvest dividend payments from blue chips, you can use them to live on while still growing your principal.

Other stocks mentioned: KO, VZ, VZA
1 month ago - The Motley Fool

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

Other stocks mentioned: ABBV, BMY, GILD, JNJ, LLY, SNY
1 month ago - Kiplinger

The drugmaker needs as much potential revenue as it can acquire at a reasonable price.

Other stocks mentioned: FPRX
1 month ago - The Motley Fool

In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other sma...

Other stocks mentioned: BGNE, BMY, FPRX
1 month ago - GuruFocus

Earlier this month, biotech giant Amgen Inc (NASDAQ: AMGN) announced a $1.9 billion buyout of Five Prime Therapeutics Inc (NASDAQ: FPRX) that outlasted around 15 potential collaborators. Background: Amg...

Other stocks mentioned: FPRX
1 month ago - Benzinga

With the first quarter soon coming to an end, many investors are looking to print some solid gains for the first three months of 2021, while turning their attention to what could be a very strong second...

Other stocks mentioned: AMAT, LRCX, QRVO
1 month ago - 24/7 Wall Street

It's not getting much attention lately, but the future for Amgen looks strong.

1 month ago - The Motley Fool

THOUSAND OAKS, Calif., March 11, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the virtual Oppenheimer 31st Annual Healthcare Conference at 2:30 p.m.

1 month ago - PRNewsWire

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Other stocks mentioned: ADPT, BNTX, ILMN, MRNA, MSFT
1 month ago - The Motley Fool

Amgen (AMGN) inks a $1.9-billion deal to acquire clinical-stage biotech, Five Prime Therapeutics, to boost its oncology pipeline.

2 months ago - Zacks Investment Research

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of... [Read more...]

Industry
Drug Manufacturers-General
Founded
1980
CEO
Robert Bradway
Employees
24,300
Stock Exchange
NASDAQ
Ticker Symbol
AMGN
Full Company Profile

Financial Performance

In 2020, Amgen's revenue was $25.42 billion, an increase of 8.83% compared to the previous year's $23.36 billion. Earnings were $7.26 billion, a decrease of -7.37%.

Financial Statements

Analyst Forecasts

According to 30 analysts, the average rating for Amgen stock is "Buy." The 12-month stock price forecast is 254.40, which is an increase of 0.07% from the latest price.

Price Target
$254.40
(0.07% upside)
Analyst Consensus: Buy